http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
사염화탄소로 급성 간손상이 유발된 흰쥐에서 혈청 및 간조직의 Transforming Growth Factor-β1의 변화와 비타민 E의 효과
이상인,이정일,이관식,김현숙,전재윤,한광협,문영명,박영년,이세준,정준표 대한간학회 2000 Clinical and Molecular Hepatology(대한간학회지) Vol.6 No.2
$quot;Background/Aims: The evaluation of the relationship between oxidative stress induced by acute carbon tetrachloride (CCl4) administration and transforming growth factor-β1 (TGF-β1), and the investigation of temporal patterns of serum alanine aminotransferase (ALT) and TGF-β1 expression which may clarify the pathogenesis of CCl4 induced liver injury and thus the mechanism of liver fibrogenesis. The aim of this study was to investigate TGF-β1 expression in rats with acute CCl4 injury and effect of vitamin E (vit. E) on TGF-β1 expression. Methods: Sixty male Sprague-Dawley rats had a single intraperitoneal injection of CCl4, of which 30 rats had daily intraperitoneal injection of vit. E, starting from 2 days before CCl4 treatment until the time of their sacrifice. The group of rats with CCl4 injection only was designated as group 1 and the group of rats with vit. E combined treatment was designated as group 2. Five rats from each group were sacrificed before and 8, 16, 32, 48, 60 hours after CCl4 injection, heir serum ALT, serum TGF-β1, and hepatic expression of TGF-β1 were examined. Results: The serum ALT levels were highest at 32 hours after CCl4 injection in both groups, serum TGF-β1 levels did not show any statistically significant changes after CCl4 injection in both groups, and TGF-β1 expression in the livers was highest at 32 hours after CCl4 injection in both groups. In the multiple regression analysis of vit. E's effect on serum ALT levels, serum TGF-β1 levels and hepatic TGF-β1 expression, only serum ALT level (p=0.049) and hepatic TGF-β1 expression (p=0.015) showed statistically significant suppression. Conclusion: Oxidative stress seems to play a role in the pathogenesis of hepatic fibrogenesis by increasing TGF-β1 expression in early acute liver damage. and vit. E may be effective in reducing acute liver injury and hepatic fibrogenesis. (Korean J Hepatol 2000;6:147-155)$quot;
Lee, Hye Won,Park, Jun Yong,Lee, Jin Woo,Yoon, Ki Tae,Kim, Chang Wook,Park, Hana,Kim, Young Seok,Paik, Soon Ku,Lee, Jung Il,Kim, Beom Kyung,Han, Kwang-Hyub,Ahn, Sang Hoon Elsevier 2019 Clinical gastroenterology and hepatology Vol.17 No.7
<P><B>Background & aims</B></P> <P>There are no globally agreed upon treatment guidelines for patients with chronic hepatitis B virus (HBV) with multidrug resistance (MDR). We conducted a multicenter, prospective, real-world cohort study of effects of tenofovir disoproxyl fumarate (TDF) monotherapy and TDF-based combination therapy, as rescue therapy, in patients with multidrug-resistant chronic HBV infections.</P> <P><B>Methods</B></P> <P>We recruited patients with chronic HBV infection with resistance to antivirals from 8 tertiary hospitals in Korea. Patients (n=423) received rescue therapy with TDF monotherapy (n=174) or TDF-based combination therapy (n=249<B>).</B> The median follow-up period was 180 weeks. A virologic response was defined as a serum HBV DNA level of <20 IU/mL.</P> <P><B>Results</B></P> <P>Cumulative rates of virologic response did not differ significantly between the groups that received TDF monotherapy vs combination therapy at 48 weeks (71.7% vs 68.9%), 96 weeks (85.1% vs 84.2%), 144 weeks (92.1% vs 92.7%), 192 weeks (93.4% vs 95.7%), or 240 weeks (97.7% vs 97.2%). Serum levels of HBV DNA below 4.0 log<SUB>10</SUB> IU/mL (odds ratio, 2.478; 95% CI 1.959–3.135; <I>P <</I> .001) and the absence of mutations associated with resistance to adefovir (odds ratio, 1.570; 95% CI 1.279–1.926; <I>P <</I> .001) were associated with virologic response in patients with MDR. There was no significant difference of virologic response among patients of different ages, sex, patients with vs without cirrhosis, positivity for hepatitis B e antigen, or renal function (all <I>P</I> > .05).</P> <P><B>Conclusion</B></P> <P>In a multicenter, real-world cohort study, long-term use of TDF monotherapy showed non-inferior antiviral efficacy compared with that of TDF-based combination therapy in patients with MDR.</P>
Lee, Jung Min,Kim, Hyung Joon,Park, Jun Yong,Lee, Chun Kyon,Kim, Do Young,Kim, Ja Kyung,Lee, Hyun Woong,Paik, Yong Han,Lee, Kwan Sik,Han, Kwang-Hyub,Chon, Chae Yoon,Hong, Sun Pyo,Nguyen, Tin,Ahn, Sang International Medical Press 2009 ANTIVIRAL THERAPY Vol.14 No.5
<P>BACKGROUND: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. METHODS: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. RESULTS: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351), HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%), IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. CONCLUSIONS: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.</P>
Han Hyub Lee,Seung-Hyun Cho,Sang Soo Lee IEEE 2010 IEEE photonics technology letters Vol.22 No.20
<P>In spectrum-sliced wavelength-division-multiplexing (WDM) passive optical networks (PONs) based on injection-seeded reflective semiconductor optical amplifiers, the inevitable spectral filtering by multiplexer/demultiplexer leads to an increase in excess intensity noise (EIN). The increased EIN degrades the signal-to-noise ratio of the modulated optical signal. To reduce the EIN, we utilized flat-top passband arrayed waveguide gratings and a narrow-bandwidth seed light source in a WDM-PON. The feasibility of a 32 1.25-Gb/s WDM-PON with 100-GHz channel spacing over a 20-km single-mode fiber was successfully demonstrated with a negligible power penalty.</P>
만성신부전을 동반한 신장의 Oncocytomatosis 1예
이종욱,최현주,한진석,이정상,이창선,김연수,김성권,이서진,안규리,강지향,이공섭,홍종서,황보빈,김승협 대한신장학회 2000 Kidney Research and Clinical Practice Vol.19 No.6
Renal oncocytomas account for approximately 5% of renal parenchymal tumors. Usually it has unilateral solitary oncocytic nodule, but bilateral multifocal renal oncocytomasis is rare. The term renal oncocytoma should be used to characterize a well-differentiated renal epithelial tumor with eosinophilic granular cytoplasm that has benign behavior and favourable progress. Also, multiple oncocytoma distributed diffusely in both kidneys is termed renal oncocytomatosis. Because of the benign nature, multicentricity, possible bilaterality and absence of pathognomonic radiographic features, renal oncocytomas should be considered in differential diagnosis of solid masses, especially renal cell carcinoma. We report a patient with bilaleral multifocal renal oncocytomatosis, who had progressive renal failure. Renal oncocytomatosis was diagnosed pathologically after bilateral nephrectomy.
Lee Sang Hyub,Choe Jung Wan,Cheon Young Koog,Choi Miyoung,Jung Min Kyu,Jang Dong Kee,Jo Jung Hyun,Lee Jae Min,Kim Eui Joo,Han Sung Yong,Choi Young Hoon,Seo Hyung-Il,Lee Dong Ho,Lee Hong Sik 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.1
Acute pancreatitis can range from a mild, self-limiting disease requiring no more than supportive care, to severe disease with life-threatening complications. With the goal of providing a recommendation framework for clinicians to manage acute pancreatitis, and to contribute to improvements in national health care, the Korean Pancreatobiliary Association (KPBA) established the Korean guidelines for acute pancreatitis management in 2013. However, many challenging issues exist which often lead to differences in clinical practices. In addition, with newly obtained evidence regarding acute pancreatitis, there have been great changes in recent knowledge and information regarding this disorder. Therefore, the KPBA committee underwent an extensive revision of the guidelines. The revised guidelines were developed using the Delphi method, and the main topics of the guidelines include the following: diagnosis, severity assessment, initial treatment, nutritional support, convalescent treatment, and the treatment of local complications and necrotizing pancreatitis. Specific recommendations are presented, along with the evidence levels and recommendation grades.